Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Shares Rise on Earnings, Coronavirus Work

By Jim Crumly – Updated Feb 6, 2020 at 2:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two drugs drove its fourth-quarter sales growth, and the company expects to have an experimental treatment for 2019n-CoV coronavirus in a few months.

Regeneron Pharmaceuticals (REGN -1.85%) reported fourth-quarter results that beat expectations, and investors -- who have been snapping up the stock this week based on news that it's working on a treatment for the 2019n-CoV coronavirus -- bid up the shares another 5%. Revenue rose 13% in the quarter to $2.17 billion, topping analysts' consensus estimate of $2.11 billion. Non-GAAP earnings per share rose 10% to $7.50, beating expectations of $6.92.

Regeneron's growth was driven by its eye drug Eylea, sales of which were up 11% in the quarter, and inflammation-reducer Dupixent, which had global sales growth of 136%. The company partners with Bayer for Eylea sales outside the U.S., and with Sanofi for worldwide sales of Dupixent.

Pipepette dropping sample into a test tube.

Image source: Getty Images.

Management declined to provide guidance for 2020, saying it was restructuring its collaboration agreement with Sanofi for two of its drugs, but said on the conference call that it was "comfortable" with the current analyst consensus, which is for non-GAAP EPS growth of 6% to $26.14.

Regeneron announced on Tuesday that it's collaborating with the U.S. Department of Health and Human Services to develop an antiviral treatment for the 2019n-CoV coronavirus, and said on the conference call that it will have the first iteration within a few months. The large-cap biotech company has a rapid-response infectious disease platform that produced a three-antibody cocktail for Ebola that proved superior to the existing standard antiviral treatment in a trial last year. Regeneron's stock has risen 15% since that announcement.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$731.86 (-1.85%) $-13.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.